🇺🇸 Bupivacaine-Lidocaine in United States

13 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fracture — 2 reports (15.38%)
  2. Musculoskeletal Pain — 2 reports (15.38%)
  3. Pain — 2 reports (15.38%)
  4. Acute Kidney Injury — 1 report (7.69%)
  5. Agitation — 1 report (7.69%)
  6. Anaemia — 1 report (7.69%)
  7. Arthralgia — 1 report (7.69%)
  8. Asthenia — 1 report (7.69%)
  9. Azotaemia — 1 report (7.69%)
  10. Back Pain — 1 report (7.69%)

Source database →

Bupivacaine-Lidocaine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Bupivacaine-Lidocaine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Bupivacaine-Lidocaine in United States?

Hospital de San Carlos Dr. Benicio Arzola Medina is the originator. The local marketing authorisation holder may differ — check the official source linked above.